Biotussin DAC and Latanoprost

• Generic Name: codeine / guaifenesin / pseudoephedrine
• Dosage Forms: n.a.
• Other Brand Names: Ambifed CD, Biotussin DAC, Cheratussin DAC, Guaifen DAC, Lortuss EX, Maxifed-G CD, Nucofed Pediatric Expectorant, Tricode GF, Tusnel C, Virtussin DAC, Virtussin DAC

Codeine is a narcotic cough suppressant. It affects the signals in the brain that trigger cough reflex.

Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.

Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Biotussin DAC is a combination medicine used to treat cough, stuffy nose, and sinus congestion caused by allergies, the common cold, or the flu.

Biotussin DAC will not treat a cough that is caused by smoking, asthma, or emphysema.

Biotussin DAC may also be used for purposes not listed in this medication guide.

• Generic Name: latanoprost ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Xalatan, Xelpros, Xalatan Multi-Pack

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. One of several first-line agents to reduce elevated IOP.

Safety and efficacy not established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.

Appears to be more effective than unoprostone, as effective as travoprost, and slightly less effective than bimatoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension.

May be more effective or at least as effective as twice daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Appears to be more effective than thrice-daily administration of dorzolamide 2%.

May be used in conjunction with a topical β-adrenergic blocking agent (e.g., betaxolol, carteolol, levobunolol, metipranolol, timolol), topical dipivefrin, topical epinephrine, an oral carbonic anhydrase inhibitor (e.g., acetazolamide), or a topical carbonic anhydrase inhibitor (e.g., dorzolamide).

Tolerance does not occur, and reduction in mean IOP is maintained for up to at least 24 months of therapy after initial stabilization.